Study data suggests IGV-001 provides patients with a clinically meaningful improvement in overall survival (+6.3 months; +45%) compared to the current standard of care for ndGBM –– Company plans to ...

Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the ...

Tema ETFs (“Tema”), the New York-based manager of innovative exchange-traded funds (ETFs), is pleased to announce the Tema Oncology ETF (“CANC”) has surpassed $100m in assets under management (AUM) ...

UK-US deal is good news for NHS patients and will help to support UK life sciences competitiveness, says ABPI Industry hopes ...